Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET

Company Participants

Lindsey Allen - Head of Investor Relations & Communications

Justin Klee - Co-Chief Executive Officer

Margaret Olinger - Chief Commercial Officer

Jim Frates - Chief Financial Officer

Josh Cohen - Co-Chief Executive Officer

Conference Call Participants

Corinne Jenkins - Goldman Sachs

Geoff Meacham - Bank of America

Michael DiFiore - Evercore

Marc Goodman - Leerink Partners

Graig Suvannavejh - Mizuho

Ananda Ghosh - H.C. Wainwright

Operator

Good afternoon. My name is Tom, and I will be your conference operator today. At this time I would like to welcome everyone to the Amylyx Pharmaceuticals Second Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode. After today’s presentation, there will be an opportunity to ask questions. [Operator instructions] Please be advised that this call is being recorded at the company's request.

I would now like to turn the conference over to Lindsey Allen Head of Investor Relations and Communications. Please go ahead.

Lindsey Allen

Good afternoon and thank you for joining us today to discuss our second quarter 2023 earnings. With me on the call are Josh Cohen and Justin Klee, our Co-CEOs; Margaret Olinger, our Chief Commercial Officer; and Jim Frates, our Chief Financial Officer.

Before we begin, I would like to remind everyone that any statements we make or information presented on this call that are not historical facts are forward-looking statements that are made based on our current beliefs, plans and expectations and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

These statements include but are not limited to our expectations with respect to RELYVRIO and ALBRIOZA, statements regarding our clinical trial and regulatory developments and the expected timing thereof, our business strategy and outlook and our expected financial performance. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC. You are cautioned not to place any undue reliance on these forward-looking statements and Amylyx disclaims any obligation to update such statements unless required by law.

Now, I will turn the call over to Justin.

Justin Klee

Thank you, Lindsey, and good afternoon. In the second quarter, we made significant progress in bringing RELYVRIO and ALBRIOZA to people with ALS in the US and Canada respectively and advancing our mission of one day ending the suffering caused by ALS and other neurodegenerative diseases.